JNJ-7706621 also shows some inhibition to VEGF-R2, FGF-R2, and GSK3¦Â, with IC50 of 154¨C254 nM. JNJ-7706621 shows inhibitory effect on a panel of human cancer cell types, including HeLa, HCT-116, SK-OV-3, PC3, DU145, A375, MDA-MB-231, MES-SA, and MES-SA/Dx5, with IC50 of 112¨C514 nM, independent of p53, retinoblastoma, or P-glycoprotein status. JNJ-7706621 is several-fold less potent at inhibiting growth of normal cell types, including MRC-5, HASMC, HUVEC, and HMVEC, with IC50 of 3.67¨C5.42 ¦ÌM. In HeLa or U937 cells, JNJ-7706621 (0.5¨C3 ¦ÌM) delays exit from G1, arrests cells in G2-M, induces endoreduplication, activates apoptosis, and reduces colony formation. In a HeLa cell line, incremental treatment with increasing concentrations of JNJ-7706621 leads to a 16-fold resistance, which may be mediated by ABCG2

June 21, 2017

prudect name : JNJ-7706621 also shows some inhibition to VEGF-R2, FGF-R2, and GSK3¦Â, with IC50 of 154¨C254 nM. JNJ-7706621 shows inhibitory effect on a panel of human cancer cell types, including HeLa, HCT-116, SK-OV-3, PC3, DU145, A375, MDA-MB-231, MES-SA, and MES-SA/Dx5, with IC50 of 112¨C514 nM, independent of p53, retinoblastoma, or P-glycoprotein status. JNJ-7706621 is several-fold less potent at inhibiting growth of normal cell types, including MRC-5, HASMC, HUVEC, and HMVEC, with IC50 of 3.67¨C5.42 ¦ÌM. In HeLa or U937 cells, JNJ-7706621 (0.5¨C3 ¦ÌM) delays exit from G1, arrests cells in G2-M, induces endoreduplication, activates apoptosis, and reduces colony formation. In a HeLa cell line, incremental treatment with increasing concentrations of JNJ-7706621 leads to a 16-fold resistance, which may be mediated by ABCG2
JNJ7706621

Synonyms: CAS NO: 443797-96-4Molecular Formula: C₁₅H₁₂F₂N₆O₃SMolecular Weight: 394.36Purity: 99%Solubility: In DMSOStorage: −20°C

ARRY 520 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18520976